Silverfin false 31/05/2023 09/05/2022 31/05/2023 Lucy Rose Obolensky 09/05/2022 31 January 2024 The principal activity of the Company during the financial year was that of advanced medical training and courses. 14095776 2023-05-31 14095776 bus:Director1 2023-05-31 14095776 core:CurrentFinancialInstruments 2023-05-31 14095776 core:ShareCapital 2023-05-31 14095776 core:RetainedEarningsAccumulatedLosses 2023-05-31 14095776 bus:OrdinaryShareClass1 2023-05-31 14095776 2022-05-09 2023-05-31 14095776 bus:FullAccounts 2022-05-09 2023-05-31 14095776 bus:SmallEntities 2022-05-09 2023-05-31 14095776 bus:AuditExemptWithAccountantsReport 2022-05-09 2023-05-31 14095776 bus:PrivateLimitedCompanyLtd 2022-05-09 2023-05-31 14095776 bus:Director1 2022-05-09 2023-05-31 14095776 bus:OrdinaryShareClass1 2022-05-09 2023-05-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 14095776 (England and Wales)

ENDEAVOUR MEDICAL LTD

Unaudited Financial Statements
For the financial period from 09 May 2022 to 31 May 2023
Pages for filing with the registrar

ENDEAVOUR MEDICAL LTD

Unaudited Financial Statements

For the financial period from 09 May 2022 to 31 May 2023

Contents

ENDEAVOUR MEDICAL LTD

STATEMENT OF FINANCIAL POSITION

As at 31 May 2023
ENDEAVOUR MEDICAL LTD

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 May 2023
31.05.2023
£
Current assets
Debtors 3 44,339
Cash at bank and in hand 41,392
85,731
Creditors: amounts falling due within one year 4 ( 33,306)
Net current assets 52,425
Total assets less current liabilities 52,425
Net assets 52,425
Capital and reserves
Called-up share capital 5 1
Profit and loss account 52,424
Total shareholder's funds 52,425

For the financial period ending 31 May 2023 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of Endeavour Medical Ltd (registered number: 14095776) were approved and authorised for issue by the Director on 31 January 2024. They were signed on its behalf by:

Lucy Rose Obolensky
Director
ENDEAVOUR MEDICAL LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 09 May 2022 to 31 May 2023
ENDEAVOUR MEDICAL LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 09 May 2022 to 31 May 2023
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.

General information and basis of accounting

Endeavour Medical Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 71-75 Shelton Street, Covent Garden, WC2H 9JQ, London, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Statement of Financial Position date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Statement of Income and Retained Earnings in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

2. Employees

Period from
09.05.2022 to
31.05.2023
Number
Monthly average number of persons employed by the Company during the period, including the director 1

3. Debtors

31.05.2023
£
Trade debtors 36,650
VAT recoverable 7,689
44,339

4. Creditors: amounts falling due within one year

31.05.2023
£
Trade creditors 3,277
Amounts owed to director 14,474
Accruals 3,000
Taxation and social security 12,555
33,306

5. Called-up share capital

31.05.2023
£
Allotted, called-up and fully-paid
1 Ordinary share of £ 1.00 1

6. Related party transactions

Transactions with the entity's director

31.05.2023
£
Amounts owed by/(to) the director (14,474)

Interest has not been charged on directors' loan accounts in the accounting period. There are no fixed dates for repayment.